Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06288711 · ClinicalTrials.gov registry record · NA
Novel Telemedicine-Delivered Prolonged Exposure Therapy for Treating PTSD in Individuals With OUD
A NA study of Post Traumatic Stress Disorder and Opioid Use Disorder, sponsored by University of Vermont.
- Recruiting
- Registry status
- NA
- Development phase
- 135
- Enrollment target
- 1
- Study location
NCT06288711: Recruiting NA study of Post Traumatic Stress Disorder and Opioid Use Disorder, sponsored by University of Vermont.
NCT06288711 is a NA study of Post Traumatic Stress Disorder and Opioid Use Disorder that is actively recruiting participants, run by University of Vermont. The registered enrollment target is 135 participants, below the 663-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06288711, a NA study of Post Traumatic Stress Disorder and Opioid Use Disorder, is actively recruiting participants, sponsored by University of Vermont.
- RECRUITING
- Registry status
- NA
- Development phase
- 135 participants
- Enrollment target
- 1
- Study location
Study Summary
Among individuals with opioid use disorder (OUD), posttraumatic stress disorder (PTSD) presents a significant clinical challenge. The prevalence of PTSD is substantially higher in individuals with OUD than in the general population, with nearly 90% reporting lifetime trauma exposure and 33% meeting diagnostic criteria for PTSD. The primary objective of this study is to evaluate the efficacy of a novel telemedicine-delivered prolonged exposure therapy protocol for improving PE attendance and reducing PTSD symptom severity in individuals with concurrent PTSD and OUD.
Primary Outcome
Percentage of scheduled prolonged exposure therapy sessions attended
Conditions Studied
Interventions
- BEHAVIORAL Treatment as usual
- BEHAVIORAL Prolonged exposure therapy
- BEHAVIORAL Financial incentives
Study Locations (1)
Vermont
- University of Vemont - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2024-06-03 |
| Est. Completion | 2027-11-30 |
| Phase | NA |
What NCT06288711 shows while recruiting
NCT06288711 is an interventional study that assigns participants to a tested intervention. The registered 135 participants enrollment target is mid-sized for trials with a published cap, below the 663-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (80% lower).
The record links to 2 conditions, with Post Traumatic Stress Disorder appearing as the primary indexed condition, and to 3 interventions - of which Treatment as usual is the first listed.
NCT06288711 reports a single indexed study location in Vermont.
Frequently Asked Questions
What is clinical trial NCT06288711 about?
NCT06288711 is a clinical study titled "Novel Telemedicine-Delivered Prolonged Exposure Therapy for Treating PTSD in Individuals With OUD". Among individuals with opioid use disorder (OUD), posttraumatic stress disorder (PTSD) presents a significant clinical challenge. The prevalence of PTSD is substantially higher in individuals with OUD than in the general population, with nearly 90% reporting lifetime trauma exposure and 33% meeting ...
What is the current status of trial NCT06288711?
This trial is currently recruiting. It is a NA study. The enrollment target is 135 participants. The study started on 2024-06-03. Estimated completion is 2027-11-30.
What conditions does trial NCT06288711 study?
This clinical trial studies the following conditions: Post Traumatic Stress Disorder, Opioid Use Disorder.
What interventions are being tested in trial NCT06288711?
The interventions under investigation include: Treatment as usual (BEHAVIORAL), Prolonged exposure therapy (BEHAVIORAL), Financial incentives (BEHAVIORAL).
Who is sponsoring clinical trial NCT06288711?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06288711 being conducted?
This trial has 1 study location across Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post Traumatic Stress Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06288711's enrollment target sits among peer trials
135 87th of 262 higher than 174 of 262 other Post Traumatic Stress Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Post Traumatic Stress Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exploring Virtual Reality Adventure Training Exergaming
RECRUITING · NA
-
CRISOL Mente: A Multilevel Community Intervention to Reduce Mental Health Disparities Among Latinos
RECRUITING · NA
-
TMS-fNIRS Personalized Dosing
RECRUITING · NA
-
Targeting the Default Mode Network: A TMS-fMRI Study
RECRUITING · NA
-
The Effects of Very Brief Exposure on PTSD in U.S. Combat Veterans
RECRUITING · NA
-
Fear and Avoidance in PTSD Patients
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00870129 · 135 participants · NA
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
- NCT03666000 · 135 participants · Phase 1
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- NCT04891510 · 135 participants · NA
A Comparative Analysis of REVOLVE, LipoGrafter, and Viality in Autologous Fat Grafting During Breast Surgery
- NCT05121051 · 135 participants · Phase 2
Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI